Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lidocaine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sintetica US Launches Lidocaine Hydrochloride Injection, USP 1%, 2% and 4%
Details : Lidocaine hydrochloride is a local anesthetic used in a wide variety of superficial and invasive procedures, it works by blocking sodium channels and thus decreasing the rate of contractions of the heart.
Product Name : Lidocaine Hydrochloride-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 27, 2023
Lead Product(s) : Lidocaine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AMP-100
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Harrow
Deal Size : Undisclosed
Deal Type : Acquisition
Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sintetica
Details : AMP-100 is a patented, innovative ocular surface anesthetic drug candidate, with safety and efficacy supported by a recently completed Phase 3 study that successfully compared the efficacy and tolerability of AMP-100 to current standards of care.
Product Name : AMP-100
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 27, 2021
Lead Product(s) : AMP-100
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Harrow
Deal Size : Undisclosed
Deal Type : Acquisition
Reset All
